GEN Exclusives

More »

GEN Exclusives

GEN Exclusives provide you with unique, in-depth, and critical coverage of key industry developments, market moving events, and scientific advances, as well as interviews with life science thought leaders. Also included are feature articles from GEN’s print edition.

Insight & Intelligence™: Sep 18, 2014

Prognostic vs. Predictive Biomarkers Landscape

Not all biomarkers are the same. Learn about the differences between these two important classes.

Prognostic vs. Predictive Biomarkers Landscape

Classifying biomarkers based upon their value proposition vis-à-vis clinical utility is fundamental to the successful deployment of targeted therapeutics in the future. [dream designs – Shutterstock]

    The focus of this GEN Market & Tech Analysis report is to provide an update on the prognostic and predictive biomarkers market landscape.


    • GEN explores in this report the segmentation of prognostic versus predictive biomarkers; this distinction is important as it underlines their clinical potential.
    • The deployment of personalized medicine in oncology and beyond requires a precise understanding of disease progression as well as molecular targeting of therapies in order to “interrogate” the molecular lesion—prognostic and predictive biomarkers have the power to effect these two functions, respectively.
    • Indeed, there are a large number of putative biomarkers postulated in the literature but very few have successfully been utilized in the clinic—if personalized medicine is to expand and scale across therapeutic classes its important for many more biomarkers to emanate and find clinical utility.
    • In the future, we believe that other classes of biomarkers such as circulating biomarkers, microRNAs, as well as epigenetic modifications may serve to broaden the repertoire of prognostic and predictive biomarkers.

Add a comment

  • Add a comment

  • Click here to Login/Register for free. You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?